Compare INDI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | KURA |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.1M | 841.6M |
| IPO Year | 2021 | 2015 |
| Metric | INDI | KURA |
|---|---|---|
| Price | $3.48 | $9.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $6.25 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 4.8M | 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,394,000.00 | $67,482,000.00 |
| Revenue This Year | $25.54 | $28.28 |
| Revenue Next Year | $38.45 | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.33 | ★ 25.24 |
| 52 Week Low | $2.32 | $5.45 |
| 52 Week High | $6.05 | $12.49 |
| Indicator | INDI | KURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.